Is niacin ineffective? Or did AIM-HIGH miss its target?
other
Where this comes from
- Record sourced from PubMed, PMID 22219232.
- Also identified by DOI 10.3949/ccjm.79a.11166.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) found, in an interim analysis, no cardiovascular benefit from taking extended-release niacin (Niaspan). In fact, there was a trend toward a greater risk of ischemic stroke, which did not reach statistical significance. But questions remain about this complex trial, which included intensive statin therapy in the active-treatment group and the control group.
Medical subject headings
- Brain Ischemia
- Coronary Artery Disease
- Dyslipidemias
- Niacin
- Vitamin B Complex